Oxford Asset Management LLP Buys Shares of 4,182 Incyte Co. (NASDAQ:INCY)

Oxford Asset Management LLP bought a new stake in shares of Incyte Co. (NASDAQ:INCY) in the 4th quarter, Holdings Channel reports. The firm bought 4,182 shares of the biopharmaceutical company’s stock, valued at approximately $289,000.

Other large investors have also modified their holdings of the company. Quintet Private Bank Europe S.A. bought a new stake in shares of Incyte during the fourth quarter valued at approximately $26,000. Global X Japan Co. Ltd. raised its stake in shares of Incyte by 144.7% during the fourth quarter. Global X Japan Co. Ltd. now owns 389 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 230 shares in the last quarter. R Squared Ltd bought a new stake in shares of Incyte during the fourth quarter valued at approximately $30,000. Blue Trust Inc. raised its stake in shares of Incyte by 124.6% during the fourth quarter. Blue Trust Inc. now owns 593 shares of the biopharmaceutical company’s stock valued at $39,000 after acquiring an additional 329 shares in the last quarter. Finally, Bradley & Co. Private Wealth Management LLC bought a new stake in shares of Incyte during the fourth quarter valued at approximately $42,000. Hedge funds and other institutional investors own 96.97% of the company’s stock.

Insider Activity at Incyte

In related news, EVP Barry P. Flannelly sold 19,807 shares of the business’s stock in a transaction on Friday, March 14th. The stock was sold at an average price of $67.69, for a total value of $1,340,735.83. Following the sale, the executive vice president now owns 33,567 shares in the company, valued at approximately $2,272,150.23. The trade was a 37.11 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Sheila A. Denton sold 599 shares of the stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $69.99, for a total value of $41,924.01. Following the completion of the sale, the executive vice president now directly owns 25,848 shares in the company, valued at $1,809,101.52. This represents a 2.26 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 34,475 shares of company stock worth $2,424,751. 17.60% of the stock is currently owned by company insiders.

Incyte Stock Performance

NASDAQ INCY opened at $59.16 on Monday. The stock’s fifty day moving average is $63.63 and its two-hundred day moving average is $69.05. The firm has a market capitalization of $11.45 billion, a P/E ratio of 219.12, a price-to-earnings-growth ratio of 0.41 and a beta of 0.89. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.94 and a current ratio of 1.97. Incyte Co. has a fifty-two week low of $50.35 and a fifty-two week high of $83.95.

Incyte (NASDAQ:INCY) last announced its quarterly earnings results on Monday, February 10th. The biopharmaceutical company reported $1.09 EPS for the quarter, missing the consensus estimate of $1.57 by ($0.48). Incyte had a net margin of 0.77% and a return on equity of 0.05%. On average, research analysts anticipate that Incyte Co. will post 4.86 earnings per share for the current year.

Analyst Ratings Changes

Several analysts have recently weighed in on INCY shares. StockNews.com downgraded shares of Incyte from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, February 12th. JPMorgan Chase & Co. decreased their price target on shares of Incyte from $70.00 to $68.00 and set a “neutral” rating for the company in a research note on Monday, April 21st. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Incyte in a research note on Friday, January 10th. Royal Bank of Canada lowered their target price on Incyte from $70.00 to $68.00 and set a “sector perform” rating for the company in a report on Tuesday, February 11th. Finally, Citigroup lowered their target price on Incyte from $97.00 to $88.00 and set a “buy” rating for the company in a report on Tuesday, February 11th. One research analyst has rated the stock with a sell rating, thirteen have given a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $74.69.

About Incyte

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.